Abbott Laboratories

Abbott Laboratories

ABTNYSE / NASDAQHealthcareLarge cap

$103.00-$0.87 (-0.8%)

Last close · Data as of Nov 20, 2026

Market cap
$158.1B
P/E
24.2x
EV / EBITDA
13.5x
Revenue
$44.3B
Net margin
14.7%
ROCE
11.5%

-16.9% over the last year

Abbott Laboratories price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+0.5%
3M
-9.8%
6M
+16.5%
1Y
-16.9%
5Y
-18.8%

52-week range

Day change -$0.87 (-0.8%) from $104 to $103 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ABT, bought on each weekday since 2021.

News & filings

What Abbott Laboratories filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernReturn on equity fell from 28.1% to 12.5% between fiscal 2024 and fiscal 2025.

Strengths (1)

  • Operating profit was 18.2 times interest costs.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Read moreShow less

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. The company also provides cancer screening and diagnostic test products. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Sector
Healthcare
Shares outstanding
1.74B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$158.1B
P/E
24.2x
P/B
3.0x
EV / EBITDA
13.5x
EV / Sales
3.7x
P/S
3.6x
52-week high
$128.90
52-week low
$82.56

Profitability

Operating margin
18.2%
Net margin
14.7%
EBITDA margin
27.2%
ROE
12.5%
ROCE
11.5%
ROA
7.5%
Asset turnover
0.51

Growth

Revenue
$44.3B
Revenue growth, 1Y
5.7%
Revenue CAGR, 3Y
0.5%
Net profit growth, 1Y
-51.3%
Free cash flow
$7.4B

Solvency

Current ratio
1.58
Debt / Equity
0.27
Debt / Assets
0.16
CFO / Net profit
1.47
Cash / Market cap
5.4%

Where the revenue went

Of every $100 of FY2025 revenue, $15 was left as net income.

Abbott Laboratories income statement flow, FY2025
Abbott Laboratories income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$19.3B
RevenueGross profit$25.0B
Gross profitResearch and development$2.9B
Gross profitSelling, general and administrative$12.3B
Gross profitOther operating expenses$1.7B
Gross profitOperating income$8.1B
Operating incomePretax income$8.1B
Interest and other incomePretax income$413.0M
Pretax incomeTax and other$1.9B
Pretax incomeNet income$6.5B

Revenue and net profit

Revenue grew 5.7% in FY2025; net profit is the dashed line.

Abbott Laboratories revenue and net profit by fiscal year
Abbott Laboratories revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$43.7B$6.9B
FY2023$40.1B$5.7B
FY2024$42.0B$13.4B
FY2025$44.3B$6.5B

Cash flows

FY2025: $9.6B from operations, $7.4B free after investment (dashed).

Abbott Laboratories operating and free cash flow by fiscal year
Abbott Laboratories operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$9.6B$7.8B
FY2023$7.3B$5.1B
FY2024$8.6B$6.4B
FY2025$9.6B$7.4B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$44.3B+5.7%1Y
EBITDA
$12.1B+11.9%1Y
Net profit
$6.5B-51.3%1Y
Cash from operations
$9.6B+11.8%1Y
Free cash flow
$7.4B+16.4%1Y
Revenue CAGR, 3Y
0.5%
Net profit CAGR, 3Y
-2.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$44.3B$12.1B$6.5B$7.4B12.5%+5.7%-51.3%

Monthly returns

Month-by-month returns of ABT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$86.7B
Liabilities$33.9B
Equity$52.8B
Retained earnings$49.8B
Treasury stock$17.2B
Minority interest$641.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ABT highlighted.

P/E against peers

ABT trades at 24.2x earnings against a peer median of 25.5x.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Abbott LaboratoriesABTthis company$158.1B24.2x3.0x12.5%13.5x
Amgen Inc.AMGN$186.5B24.2x21.5x89.1%13.7x
Thermo Fisher Scientific Inc.TMO$179.1B26.7x3.4x12.6%18.1x
Gilead Sciences, Inc.GILD$160.4B18.8x7.1x37.5%12.9x
Intuitive Surgical, Inc.ISRG$148.3B51.9x8.3x16.0%39.3x
Pfizer Inc.PFE$146.4B18.8x1.7x9.0%12.5x
Danaher CorporationDHR$132.1B36.6x2.5x6.9%21.2x
CVS Health CorporationCVS$121.0B68.4x1.6x2.4%19.5x
Bristol-Myers Squibb CompanyBMY$115.6B16.4x6.3x38.2%10.0x
Peer median—25.5x4.8x14.3%15.9x

Year-to-date ROI

ABT since 1 January, against earlier years.

Historical volatility

ABT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Abbott Laboratories operating margin by fiscal year
Abbott Laboratories operating margin by fiscal year
DateOperating margin
FY202219.2%
FY202316.2%
FY202416.3%
FY202518.2%
LineFY2025
Cost of revenueCost Of Revenue$19.3B
Gross profitGross Profit$25.0B
Operating expensesOperating Expense$17.0B
Research and developmentResearch And Development$2.9B
Selling, general and administrativeSelling General And Administration$12.3B
Depreciation and amortisationDepreciation And Amortization In Income Statement$1.7B
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$1.7B
Amortization$1.7B
Amortisation of intangiblesAmortization Of Intangibles Income Statement$1.7B
Total expensesTotal Expenses$36.3B
Pretax incomePretax Income$8.5B

Learn while you research

Academy chapters picked for Abbott Laboratories and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →